Results from ALICE - Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial

被引：0
|
作者：
Kyte, Jon Amund
Rossevold, Andreas H.
Andresen, Nikolai K.
Bjerre, Christina Annette
Gilje, Bjornar
Jakobsen, Erik Hugger
Raj, Sunil Xavier
Falk, Ragnhild Sorum
Borgen, Elin
Jahr, Thea
Garred, Oystein
Lomo, Jon
Mathiesen, Randi Margit
Naume, Bjorn
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD11-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD11-11
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer.Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer.
    Yuan, Yuan
    Ge, Xuan
    Yost, Susan Elaine
    Lee, Jin Sun
    Frankel, Paul Henry
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Mortimer, Joanne E.
    Waisman, James Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
    Brufsky, A.
    Kim, S. B.
    Zvirbule, Z.
    Eniu, A.
    Mebis, J.
    Sohn, J. H.
    Wongchenko, M.
    Chohan, S.
    Amin, R.
    Yan, Y.
    McNally, V
    Miles, D.
    Loi, S.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 652 - 660
  • [23] Phase II trial of selinexor for metastatic triple negative breast cancer
    Han, H. S.
    Ismail-Khan, R.
    Carney, D.
    Extermann, M.
    Hogue, D.
    Soliman, H.
    Loftus, L.
    Lee, J. K.
    Sullivan, D.
    CANCER RESEARCH, 2017, 77
  • [24] A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
    Huang, Jia-Yi
    Xie, Xiao-Feng
    Chen, Xue-Lian
    Zhang, Qiu-Yi
    Chen, Li-Ping
    Bai, Xue
    Lan, Xiao-Feng
    Song, Lin
    Guo, Jin-Feng
    Du, Cai-Wen
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
    Lander, Eric Michael
    Lehmann, Brian David
    Shah, Payal D.
    Dees, Elizabeth Claire
    Ballinger, Tarah Jean
    Pohlmann, Paula Raffin
    Santa-Maria, Cesar Augusto
    Shyr, Yu
    Mayer, Ingrid A.
    Park, Ben Ho
    Pietenpol, Jennifer A.
    Abramson, Vandana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze)
    Loibl, Sibylle
    Jackisch, Christian
    Seiler, Sabine
    Rastogi, Priya
    Huober, Lens
    Denkert, Carsten
    Schneeweiss, Andreas
    Hanusch, Claus
    Fasching, Peter A.
    Blohmer, Jens-Uwe
    Untch, Michael
    Rhiem, Kerstin
    Solbach, Christine
    Nekljudova, Valentina
    Costantino, Joseph
    Wolmark, Norman
    Geyer, Charles
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 24 - 25
  • [27] A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Graham, Noah
    Bi, Kevin
    Park, Jihye
    Fu, Jingxin
    Keenan, Tanya
    Richardson, Edward Thomas
    Pastorello, Ricardo
    Lange, Paulina
    Attaya, Victoria
    Wesolowski, Robert
    Sinclair, Natalie
    Lucas, Zarah
    Lo, Steve
    Tung, Nadine
    Faggen, Meredith
    Kaufman, Peter A.
    Block, Caroline C.
    Briccetti, Fred
    Toke, Madhavi
    Chen, Wendy
    Wucherpfennig, Kai
    Marx, Sascha
    Agudo, Judith
    Guerriero, Jennifer L.
    Schnitt, Stuart
    Lin, Nancy U.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tayob, Nabihah
    Van Allen, Eliezer
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [28] Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess)
    Golshan, Mehra
    Loibl, Sibylle
    Huober, Jens Bodo
    O'Shaughnessy, Joyce
    Rugo, Hope S.
    Wolmark, Norman
    McKee, Mark D.
    Maag, David
    Sullivan, Danielle Marie
    Giranda, Vincent L.
    Liu, Xuan
    Von Minckwitz, Gunter
    Geyer, Charles E.
    Sikov, William M.
    Untch, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Surgical Results From the BrighTNess Randomized Clinical Trial
    Golshan, Mehra
    Loibl, Sibylle
    Wong, Stephanie M.
    Houber, Jens Bodo
    O'Shaughnessy, Joyce
    Rugo, Hope S.
    Wolmark, Norman
    McKee, Mark D.
    Maag, David
    Sullivan, Danielle M.
    Metzger-Filho, Otto
    Von Minckwitz, Gunter
    Geyer, Charles E., Jr.
    Sikov, William M.
    Untch, Michael
    JAMA SURGERY, 2020, 155 (03)
  • [30] Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
    Jasmeet Chadha Singh
    Yelena Novik
    Stacey Stein
    Matthew Volm
    Marlene Meyers
    Julia Smith
    Coral Omene
    James Speyer
    Robert Schneider
    Komal Jhaveri
    Silvia Formenti
    Victoria Kyriakou
    Benson Joseph
    Judith D Goldberg
    Xiaochun Li
    Sylvia Adams
    Amy Tiersten
    Breast Cancer Research, 16
12345